A Phase I Investigation of the Combination of MK2206, Trastuzumab and Lapatinib in HER2+ Solid Tumors.

Trial Profile

A Phase I Investigation of the Combination of MK2206, Trastuzumab and Lapatinib in HER2+ Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2015

At a glance

  • Drugs MK 2206 (Primary) ; Lapatinib; Trastuzumab
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 06 Mar 2012 Actual patients number changed from 33 to 31 as reported by ClinicalTrials.gov.
    • 09 Feb 2012 Actual end date changed from Aug 2011 to Dec 2011 as reported by ClinicalTrials.gov.
    • 26 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top